Thang Vo-Ta began his career in investment banking and private equity with Goldman Sachs in New York and London. He later spent a decade in property development, helping to deliver London landmarks such as St Pancras Chambers and the Chiltern Firehouse. Thang went on to lead a number of successful entrepreneurial ventures, earning recognition as a Sunday Times Maserati Top 100 Entrepreneur and The Manufacturer’s Top 100 manufacturing leader.

He is now the co-founder and CEO of Calla Lily Clinical Care, a women’s health company pioneering the Callavid® vaginal drug delivery platform. The company’s first indications focus on fertility and pregnancy, where the company seeks to offer the world’s first drug-device combo product to help prevent threatened miscarriage. The platform’s versatility extends to delivering menopausal therapies, targeted cancer treatments, and live biotherapeutics, with the potential to reduce antibiotic usage and combat antimicrobial resistance (AMR).

Partnering with co-founder Dr. Lara Zibners, a physician with personal IVF experience, Thang leads the company’s strategic vision and team. Under his leadership, Calla Lily Clinical Care is committed not only to scientific innovation but also to environmental and social responsibility as a certified B Corp. Thang trained at MIT and Oxford University.